Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2002

View Archived Issues

Novel COX-2 inhibitors in early development at GSK

Tachykinin antagonists for use in depression and other disorders

Synthesis of novel 5-HT2A receptor ligands reported at Medicinal Chemistry Symposium

Abbott identifies aryl tetrahydropyridine farnesyltransferase inhibitors

Biological activity of paclitaxel-glucose conjugate tested in human cancer cell lines

Discovery of CCR3 receptor antagonists with potential in allergic asthma

Novel antiinflammatory agents from Celgene act by inhibiting transcriptional activation in T-cells

A wealth of data on lumiracoxib presented at the EULAR congress

NN-2211 may be useful for treating obesity and type 2 diabetes

Preclinical findings reported for aldose reductase inhibitor fidarestat

New data on ragaglitazar discussed at the ADA scientific sessions

Lead PTP1B inhibitor with blood glucose-lowering effects identified by Korean group

Hydroxamate-based antibiotics targeting LpxC in Gram-negative bacteria

DISC-GMCSF completes phase I study

NDA filing for Purdue's abuse-resistant pain medication delayed

FSME-IMMUN vaccine approved for adult use in Germany

Chiron grants nonexclusive HCV license to Merck & Co.

Argenta Discovery and Amedis enter drug discovery collaboration

Immtech's lead hepatitis C compounds to be validated for further development

Trospium completes phase III trial in overactive bladder

CoFactor phase II trial design finalized

Asthma drug candidate selected under Texas Biotechnology/Schering-Plough collaboration

Frova launched in U.S.

Human 5-HT2C receptor ligands selected for further evaluation at Vernalis for use in obesity

Sankyo patents new antitumor compounds

3-Dimensional presents new trypsin-like protease inhibitors in recent patent

Potent inhibitors of IL-12 production and potential therapeutic applications

Mast cell stabilizers synthesized at Alcon active in model of allergic conjunctivitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...